Rhythm Pharmaceuticals (1RV) Stock Overview
A commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases in the United States and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
1RV Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Rhythm Pharmaceuticals, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$75.50 |
| 52 Week High | US$99.00 |
| 52 Week Low | US$52.00 |
| Beta | 1.94 |
| 1 Month Change | 11.85% |
| 3 Month Change | -1.31% |
| 1 Year Change | 39.81% |
| 3 Year Change | 383.97% |
| 5 Year Change | 393.46% |
| Change since IPO | 248.13% |
Recent News & Updates
Recent updates
Shareholder Returns
| 1RV | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 2.7% | 0.3% | 0.7% |
| 1Y | 39.8% | -8.2% | 2.0% |
Return vs Industry: 1RV exceeded the German Biotechs industry which returned -8.5% over the past year.
Return vs Market: 1RV exceeded the German Market which returned 2.2% over the past year.
Price Volatility
| 1RV volatility | |
|---|---|
| 1RV Average Weekly Movement | 8.6% |
| Biotechs Industry Average Movement | 8.4% |
| Market Average Movement | 6.1% |
| 10% most volatile stocks in DE Market | 13.1% |
| 10% least volatile stocks in DE Market | 2.7% |
Stable Share Price: 1RV's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: 1RV's weekly volatility (9%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2008 | 414 | David Meeker | rhythmtx.com |
Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases in the United States and internationally. The company’s lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, Bardet-Biedl and Alström syndrome, Prader-Willi syndrome, and hypothalamic obesity. It is in Phase 3 clinical trials for treating acquired hypothalamic obesity, congenital hypothalamic obesity, pro-opiomelanocortin (POMC) and LEPR insufficiency obesities, SRC1 deficiency obesity, and SH2B1 deficiency obesity; and in phase 2 clinical trails for the treatment of Prader-Willi syndrome and MC4R deficiency.
Rhythm Pharmaceuticals, Inc. Fundamentals Summary
| 1RV fundamental statistics | |
|---|---|
| Market cap | €5.46b |
| Earnings (TTM) | -€178.16m |
| Revenue (TTM) | €186.15m |
Is 1RV overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 1RV income statement (TTM) | |
|---|---|
| Revenue | US$217.17m |
| Cost of Revenue | US$23.00m |
| Gross Profit | US$194.16m |
| Other Expenses | US$402.00m |
| Earnings | -US$207.84m |
Last Reported Earnings
Mar 31, 2026
Next Earnings Date
n/a
| Earnings per share (EPS) | -3.03 |
| Gross Margin | 89.41% |
| Net Profit Margin | -95.71% |
| Debt/Equity Ratio | 45.6% |
How did 1RV perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/05/29 13:50 |
| End of Day Share Price | 2026/05/29 00:00 |
| Earnings | 2026/03/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Rhythm Pharmaceuticals, Inc. is covered by 27 analysts. 16 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Tazeen Ahmad | BofA Global Research |
| Whitney Ijem | Canaccord Genuity |
| Samantha Lynn Semenkow | Citigroup Inc |